Objective To evaluate the clinical efficacy and safety of ritonavir-boosted danoprevir (DNVr) combined with daclatasvir (DCV) in the treatment of patients with genotype 1b chronic hepatitis C (CHC).Methods Thirty-three patients with genotype 1b CHC admitted in the Department of Infectious Diseases of the First Affiliated Hospital of Nanchang University from August 2018 to February 2019 were enrolled.All the patients received DNVr +DCV antiviral treatment.HCV RNA levels were detected before and 2, 4, 12 weeks after treatment, and after drug withdrawal , respectively.Indicators of liver and kidney function and adverse events were observed.ANOVAV of repeated measurement was used to analyze the data. Results The baseline viral loads of 33 patients ranged from 1.12×104 to 1.76×107 IU／mL.Two weeks after treatment the viral loads of all patients were down to the lowest limit of detection (＜500 IU／mL). Serum ALT, AST and TBil levels returned to norml ( F＝58.26, 14.49 and 20.16, all P＜0.05) and sustained virologic response reached 100%12 weeks after drug withdrawal.Three cases had minor adverse reactions during the treatment.Conclusion DNVr combined with DCV can achieve a rapid and strong virological response in the treatment of patients with genotype 1b CHC with good safety.

Objective To evaluate the antibiotic resistance profile of the Aeromonas strains isolated from extra-intestinal specimens during 7-year period in a tertiary hospital in Chongqing for appropriate antibiotic treatment.Methods WHONET 5.6 software was used to analyze the clinical data and results of antimicrobial susceptibility testing of Aeromonas strains to 14 antibiotics according to CLSI breakpoints (CLSI-M45-A3).Results A total of 230 non-duplicate Aeromonas strains were collected from January 2010 to December 2016.The most common species were Aeromonas hydrophila (83.0％) and Aeromonas sobria (14.8％).Majority of the strains were isolated from wound secretion,bile and urine.Overall,46.8％ of the Aeromonas isolates were resistant to trimethoprim-sulfamethoxazole,followed by ceftriaxone (37.0％) and cefuroxime (28.8％).More than 10％ of the strains were resistant to aztreonam,cefepime and ciprofloxacin.More than 90％ of the strains were susceptible to piperacillin-tazobactam,cefoxitin,levofloxacin,gentamicin,amikacin,imipenem and meropenem.Only 4.0％ and 1.7％ of the strains were resistant to imipenem and meropenem,respectively.Aeromonas hydrophila showed higher antibiotic resistance than Aeromonas sobria to all the antibiotics tested except piperacillin-tazobactam,imipenem,and amikacin.None of the Aeromonas sobria isolates was found resistant to meropenem.Conclusions The Aeromonas hydrophila and Aeromonas sobria isolates are the dominant Aeromonas species in Chongqing.The antibiotic resistant profiles vary with Aeromonas species and site of infection.The use of third generation cephalosporins and trimethoprim-sulfamethoxazole should be cautious in Aeromonas infection due to the high resistance level.

Objective:To investigate the relationship between the expression of hepatocyte nuclear factor-1 α (HNF-1α) and the occurrence and development of liver inflammation and fibrosis in liver tissues of patients with chronic hepatitis B.Methods:Sixty-four patients with chronic hepatitis B who were diagnosed and treated in our hospital from 2011 to 2018 were selected. All patients underwent ultrasound-guided aspiration liver biopsy. The pathological results of liver biopsy were collected for inflammation grading and fibrosis staging. The liver puncture biopsies was collected by paraffin sectioning. The expression of HNF1α in the liver tissue was detected by immunohistochemical staining. Mantel-Haenszel χ2 test was used for bidirectional ordered grouping data, and Spearman’s rank-correlation test was used for rank correlation analysis. Results:There were varying degrees of inflammatory necrosis and fibrosis in the liver tissues of patients with chronic hepatitis B. There was a linear relationship between the expression of HNF1α and the level of inflammation in liver tissues ( χ2MH = 40.70, P < 0.05). The expression of HNF1α in liver tissues of patients with chronic hepatitis B was decreased with the increase of liver inflammation. The expression intensity of HNF1α was negatively correlated with the inflammation grade ( rs = -0.815, P < 0.05). There was a linear relationship between the expressions of HNF1α and the degree and stage of liver fibrosis ( χ2MH = 31.95, P < 0.05). The expression level of HNF1α in liver tissue was gradually decreased with the aggravation of liver fibrosis. The expression intensity of HNF1α was negatively correlated with fibrosis stage ( rs = -0.713, P < 0.05). Conclusion:HNF1α is closely related to the occurrence and development of liver tissue inflammation and fibrosis, and is expected to be a sensitive indicator for evaluating the level of liver tissue inflammation and fibrosis in patients with chronic hepatitis B. In addition, its down-regulation may be involved in the process of occurrence and development of liver inflammation and liver fibrosis, and may become a new target for the treatment of chronic hepatitis B.